A Cambridge-based biotech company that has developed an experimental treatment for the Ebola virus is urging federal officials to consider allowing the unproven medication to be used on patients who have been infected in Africa’s deadly outbreak and brought to the United States for treatment. Research by Sean P. J. Whelan, professor of microbiology and immunobiology, is cited.
News & Research
